Regeneron Pharmaceuticals Inc vs Shopify Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Shopify Inc. trades at $127.06 (market cap $172.54B). The key difference: Shopify Inc. is far larger — about 2.1× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals.
| REGN | SHOP | |
|---|---|---|
Market Cap | $83.43B | $172.54B |
Sector | Health | Technology |
52-Week High | $852.03 | $179.01 |
52-Week Low | $555.51 | $95.40 |
Enterprise Value | $78.14B | $167.77B |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Shopify (SHOP) trades at $134.10, down 7.57% amid broader market weakness. The stock shows bearish technical signals with key support at $131 and resistance at $140. Fundamentally, revenue growth remains strong at $11.56B in 2025 with improving profitability, though valuation metrics appear elevated with a P/E of 90.6. Recent earnings show mixed results with a Q4 2025 miss but subsequent beats in 2026.
Analyst consensus remains bullish with 67% buy ratings and $167.50 price target, representing 25% upside. Key risks include premium valuation compression and competitive pressures in e-commerce infrastructure. The company's expanding B2B segment and AI integration provide growth catalysts, but investors should weigh rich multiples against execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →